Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956233 | 0.93 | — | — | |
| SCHEMBL31421734 | 0.93 | — | — | |
| SCHEMBL23312 | 0.93 | — | — | |
| SCHEMBL455386 | 0.93 | ALDH1A1 (0.53) | FFAR3LCKFYNALDH1A1TSHR | |
| SCHEMBL11256487 | 0.93 | — | — | |
| SCHEMBL15820259 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL1291178 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL159297 | 0.89 | — | — | |
| SCHEMBL8902015 | 0.89 | — | — | |
| Water SCHEMBL11216754 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312606-A1 | MCL-1 INHIBITOR FORMULATIONS | AMGEN INC. (US) | 2023-10-05 | — | — | US | claimed |
| EP-4203922-A1 | MCL-1 INHIBITOR FORMULATIONS | Amgen Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116115581-A | Ketorolac tromethamine biphasic controlled release tablet and preparation method thereof | 中国人民解放军中部战区总医院 | 2023-05-16 | — | — | CN | claimed |
| EP-3821882-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| EP-2305624-B1 | Self-degradable explosive device | MAXAMCORP HOLDING SL (ES) | 2017-09-27 | — | — | EP | claimed |
| US-8585841-B2 | Systems and methods for chemical and/or mechanical remediation of nitro compounds and nitrate esters | MAXAMCORP HOLDING S.L. (ES) | 2013-11-19 | — | — | US | claimed |
| US-8529955-B2 | Methods of treatment using a gastric retained gabapentin dosage | DEPOMED, INC. (US) | 2013-09-10 | — | — | US | claimed |
| US-8440232-B2 | Methods of treatment using a gastric retained gabapentin dosage | DEPOMED, INC. (US) | 2013-05-14 | — | — | US | claimed |
| EP-2445852-A1 | SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS | Maxamcorp Holding, S.L. (ES) | 2012-05-02 | — | — | EP | claimed |
| US-20120064168-A1 | METHODS OF TREATMENT USING A GASTRIC RETAINED GABEPENTIN DOSAGE | DEPOMED, INC. (US) | 2012-03-15 | — | — | US | claimed |
| US-20050276849-A1 | Sustained release dosage forms | ANDRX CORPORATION | 2005-12-15 | — | — | US | claimed |
| US-20050208135-A1 | Monocompartment osmotic controlled drug delivery system | RANBAXY LABORATORIES LIMITED (IN) | 2005-09-22 | — | — | US | claimed |
| US-20050064036-A1 | Methods of treatment using a gastric retained gabapentin dosage | ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.) | 2005-03-24 | — | — | US | claimed |
| EP-1503740-A1 | MONOCOMPARTMENT OSMOTIC CONTROLLED DRUG DELIVERY SYSTEM | Ranbaxy Laboratories Limited (IN) | 2005-02-09 | — | — | EP | claimed |
| EP-1502591-A2 | Controlled-release formulations coated with aqueous dispersions of ethylcellulose | EURO-CELTIQUE S.A. (LU) | 2005-02-02 | — | — | EP | claimed |
| WO-2004112746-A1 | CONTROLLED RELEASE-DRUG DELIVERY SYSTEM FOR ORAL ADMINISTRATION | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2004-12-29 | — | — | WO | claimed |
| WO-2004098572-A1 | BIPHASIC RELEASE OF GLIPIZIDE FROM MONOCOMPARTMENT OSMOTIC DOSAGE FORM | RANBAXY LABORATORIES LIMITED (US) | 2004-11-18 | — | — | WO | claimed |
| WO-2003092660-A1 | MONOCOMPARTMENT OSMOTIC CONTROLLED DRUG DELIVERY SYSTEM | RANBAXY LABORATORIES LIMITED (US) | 2003-11-13 | — | — | WO | claimed |
| US-6365185-B1 | ORAL TABLET FOR DELIVERING BENEFICIAL AGENT TO MAMMAL COMPRISING CORE COMPARTMENT HAVING BENEFICIAL AGENT SURROUNDED BY UNITARY SELF-DESTRUCTING SHELL COMPRISING PLURALITY OF DISINTEGRANT PARTICLES DISPERSED WITHIN SEMIPERMEABLE MATRIX | UNIVERSITY OF CINCINNATI | 2002-04-02 | — | — | US | claimed |
| US-5540945-A | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-07-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312606-A1 | MCL-1 INHIBITOR FORMULATIONS | MCL1, BAK1, BCL2L1 | FFAR3 4783/4885LCK 3128/4885FYN 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.